Literature DB >> 10390220

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.

L Martínez-Martínez1, A Pascual, S Hernández-Allés, D Alvarez-Díaz, A I Suárez, J Tran, V J Benedí, G A Jacoby.   

Abstract

Two clinical isolates of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae were noted to be less susceptible than expected to imipenem. Both were missing outer membrane proteins that serve as channels for antibiotic entry. The role of beta-lactamase in resistance was investigated by eliminating the original ESBL and introducing plasmids encoding various ESBLs and AmpC beta-lactamase types, by studying the effect of an increased inoculum, and by evaluating interactions with beta-lactamase inhibitors. The contribution of porin deficiency was investigated by restoring a functional ompK36 gene on a plasmid. Plasmids encoding AmpC-type beta-lactamases provided resistance to imipenem (up to 64 microg/ml) and meropenem (up to 16 microg/ml) in strains deficient in porins. Carbapenem resistance showed little inoculum effect, was not affected by clavulanate but was blocked by BRL 42715, and was diminished if OmpK36 porin was restored. Plasmids encoding TEM- and SHV-type ESBLs conferred resistance to cefepime and cefpirome, as well as to earlier oxyimino-beta-lactams. This resistance was magnified with an increased inoculum, was blocked by clavulanate, and was also lowered by OmpK36 porin restoration. In addition, SHV-2 beta-lactamase had a small effect on carbapenem resistance (imipenem MIC, 4 microg/ml, increasing to 16 microg/ml with a higher inoculum) when porins were absent. In K. pneumoniae porin loss can thus augment resistance provided either by TEM- or SHV-type ESBLs or by plasmid-mediated AmpC enzymes to include the latest oxyimino-beta-lactams and carbapenems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390220      PMCID: PMC89341     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates.

Authors:  Y J Yang; P J Wu; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Enhanced resistance to cefotaxime and imipenem associated with outer membrane protein alterations in Enterobacter aerogenes.

Authors:  J M Hopkins; K J Towner
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

7.  Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins.

Authors:  A Bauernfeind; G Hörl
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

8.  Quinolone resistance from a transferable plasmid.

Authors:  L Martínez-Martínez; A Pascual; G A Jacoby
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

9.  Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.

Authors:  C Chanal; D Sirot; M Chanal; M Cluzel; J Sirot; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

10.  Molecular characterization of the gene encoding SHV-3 beta-lactamase responsible for transferable cefotaxime resistance in clinical isolates of Klebsiella pneumoniae.

Authors:  M H Nicolas; V Jarlier; N Honore; A Philippon; S T Cole
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

View more
  83 in total

1.  What's New in beta-lactamases?

Authors:  Patricia A. Bradford
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Diversity of SHV and TEM beta-lactamases in Klebsiella pneumoniae: gene evolution in Northern Taiwan and two novel beta-lactamases, SHV-25 and SHV-26.

Authors:  F Y Chang; L K Siu; C P Fung; M H Huang; M Ho
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 3.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Is OmpK35 specific for ceftazadime penetration?

Authors:  L K Siu
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.

Authors:  L Martínez-Martínez; M C Conejo; A Pascual; S Hernández-Allés; S Ballesta; E Ramírez De Arellano-Ramos; V J Benedí; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  Expression of SHV-2 beta-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems.

Authors:  Brendan Crowley; Vicente J Benedí; Antonio Doménech-Sánchez
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 8.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

9.  Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV beta-lactamase that compromises the efficacy of imipenem.

Authors:  Laurent Poirel; Claire Héritier; Isabelle Podglajen; Wladimir Sougakoff; Laurent Gutmann; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae.

Authors:  George A Jacoby; Debra M Mills; Nancy Chow
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.